Jeremy Skillington of Poolbeg Pharma: Early data read out for POLB 001 indicates a successful LPS human challenge trial
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington, CEO of discusses the positive initial data analysis in POLB 001 LPS Challenge Trial and says a full data read-out is expected in Q2 2023 following a final quality check of the unblinded data.
Highlights
- POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
- A clear dose-response relationship was demonstrated
- Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
- Full data read-out expected in Q2 2023 following a final quality check of the unblinded data
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.